Jill Adler-Moore

Summary

Affiliation: California State Polytechnic University
Country: USA

Publications

  1. ncbi Effect of tissue penetration on AmBisome efficacy
    Jill Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    Curr Opin Investig Drugs 4:179-85. 2003
  2. ncbi Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Ave, Pomona, CA 91768, USA
    Antimicrob Agents Chemother 49:4895-902. 2005
  3. ncbi Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, Pomona, 91768, USA
    Antimicrob Agents Chemother 50:2122-31. 2006
  4. ncbi Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B
    Peter J Smith
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    J Antimicrob Chemother 59:941-51. 2007
  5. ncbi Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Ave, Pomona, CA 91768, USA
    Antimicrob Agents Chemother 52:259-68. 2008
  6. ncbi AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
    Jill Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Avenue, Pomona, CA 91768, USA
    J Antimicrob Chemother 49:21-30. 2002
  7. ncbi Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine
    Jill Adler-Moore
    California State Polytechnic University Pomona, 3801 West Temple Ave, Pomona, CA 91768, USA
    Vaccine 29:4460-8. 2011
  8. ncbi Amphotericin B lipid preparations: what are the differences?
    J P Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    Clin Microbiol Infect 14:25-36. 2008
  9. ncbi Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections
    J A Olson
    Department of Biological Sciences, California State Polytechnic University, Pomona, California, USA
    Antimicrob Agents Chemother 56:218-30. 2012
  10. ncbi Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis
    Jill P Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    J Antimicrob Chemother 54:1096-102. 2004

Collaborators

  • Gerard M Jensen
  • Jon A Olson
  • Richard T Proffitt
  • Julie Schwartz
  • J A Olson
  • Peter J Smith
  • William A Ernst
  • A George
  • J Schwartz
  • D Hahka
  • R T Proffitt
  • M Cecilia Dignani
  • Jill P Adler Moore
  • David Constable
  • Hyung J Kim
  • Gary Fujii
  • Terrence M Tumpey
  • Wendy Tai
  • Airan D A Jansen
  • Donald V Cramer
  • P J Smith

Detail Information

Publications11

  1. ncbi Effect of tissue penetration on AmBisome efficacy
    Jill Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    Curr Opin Investig Drugs 4:179-85. 2003
    ....
  2. ncbi Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Ave, Pomona, CA 91768, USA
    Antimicrob Agents Chemother 49:4895-902. 2005
    ..In conclusion, the combination of liposomal amphotericin B with an echinocandin markedly improved the therapeutic outcome in murine C. glabrata systemic infection...
  3. ncbi Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, Pomona, 91768, USA
    Antimicrob Agents Chemother 50:2122-31. 2006
    ..In conclusion, although both drugs were effective in prolonging survival at 12 mg/kg, the reduced nephrotoxicity of L-AMB increased its therapeutic index, allowing for its safe and effective use at 15 or 20 mg/kg...
  4. ncbi Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B
    Peter J Smith
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    J Antimicrob Chemother 59:941-51. 2007
    ....
  5. ncbi Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products
    Jon A Olson
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Ave, Pomona, CA 91768, USA
    Antimicrob Agents Chemother 52:259-68. 2008
    ..In conclusion, the efficacy and toxicity of these two liposomal amphotericin B products were significantly different, and thus, the products were not comparable...
  6. ncbi AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience
    Jill Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, 3801 West Temple Avenue, Pomona, CA 91768, USA
    J Antimicrob Chemother 49:21-30. 2002
    ....
  7. ncbi Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine
    Jill Adler-Moore
    California State Polytechnic University Pomona, 3801 West Temple Ave, Pomona, CA 91768, USA
    Vaccine 29:4460-8. 2011
    ..These results suggest that the protective immune response elicited by this vaccine is mediated primarily by a Th2 mechanism...
  8. ncbi Amphotericin B lipid preparations: what are the differences?
    J P Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    Clin Microbiol Infect 14:25-36. 2008
    ..With proven efficacy demonstrated during the past decade, it is expected that amphotericin B lipid formulations will remain an important part of antifungal drug therapy...
  9. ncbi Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections
    J A Olson
    Department of Biological Sciences, California State Polytechnic University, Pomona, California, USA
    Antimicrob Agents Chemother 56:218-30. 2012
    ..flavus infection responded well to L-AmBi but not to caspofungin...
  10. ncbi Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis
    Jill P Adler-Moore
    Department of Biological Sciences, California State Polytechnic University, Pomona, CA 91768, USA
    J Antimicrob Chemother 54:1096-102. 2004
    ..This study was done to determine whether high dose AmBisome (4-20 mg/kg), given intermittently, could reduce the frequency of dosing needed to treat murine systemic candidiasis when compared with conventional daily treatment...
  11. ncbi Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines
    William A Ernst
    Molecular Express, Inc. 13310 S. Figueroa Street, Los Angeles, CA 90061, USA
    Vaccine 24:5158-68. 2006
    ....